AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2016

Thill, Marc; Liedtke, Cornelia

doi:10.1159/000447030

Cited by 24 publications

(187 citation statements)

References 19 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…ADCs are already being used successfully in clinical practice. The ADC T-DM1 has become the standard of care for second-line treatment of HER2+ MBC after trastuzumab/pertuzumab failure 5 . By now, trastuzumab deruxtecan (T-DXd, DS-8201), a new–optimised–ADC generation, is in clinical trials in HER2+ MBC.…”

Section: Spotlight On “Antibody Engineering”mentioning

confidence: 99%

“…ADCs werden in der Klinik bereits erfolgreich eingesetzt. Das ADC T-DM1 hat sich beim HER2+ MBC als Standard für die Zweitlinien-Behandlung nach Trastuzumab/Pertuzumab-Versagen etabliert 5 . Mittlerweile befindet sich mit Trastuzumab-Deruxtecan (T-DXd, DS-8201) eine neue – optimierte – ADC-Generation in der klinischen Prüfung beim HER2+ MBC.…”

Section: Antikörper-wirkstoff-konjugat (Adc)unclassified

“…In addition to the monoclonal antibody trastuzumab, dual antibody blockade with trastuzumab plus pertuzumab – in each case combined with preferably taxane-based chemotherapy – as well as the antibody drug conjugate (ADC) trastuzumab emtansine (T-DM1) have established themselves as effective treatment options in HER2+ breast cancer. The HER1/HER2 tyrosine kinase inhibitor lapatinib is one option for later lines of treatment in the metastatic setting 3 , 4 , 5 , 6 .…”

Section: Introductionmentioning

confidence: 99%

“…Neben dem monoklonalen Antikörper Trastuzumab haben sich die duale Antikörperblockade mit Trastuzumab plus Pertuzumab – jeweils in Kombination mit einer vorzugsweise Taxan-basierten Chemotherapie – sowie das Antikörper-Wirkstoff-Konjugat (ADC: antibody drug conjugate) Trastuzumab-Emtansin (T-DM1) als effektive Therapieoptionen beim HER2+ Mammakarzinom etabliert. Der HER1/HER2-Tyrosinkinase-Inhibitor Lapatinib ist in der metastasierten Situation eine Option für spätere Therapielinien 3 , 4 , 5 , 6 .…”

Section: Introductionunclassified

See 3 more Smart Citations

New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer

Lüftner

Peipp

2021

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

Despite therapeutic gains in the treatment of HER2-positive (HER2: human epidermal growth factor receptor 2) advanced/metastatic breast cancer, there remains an urgent need for more effective treatment options. At present, there is no definitive approved standard therapy beyond second-line treatment. One of the major challenges is overcoming treatment resistance. Depending on the underlying resistance mechanism, different strategies are being pursued for new innovative treatment concepts in HER2-positive breast cancer. Specifically designed antibodies for targeted therapy are one important focus to successfully meet these challenges. Trastuzumab deruxtecan (T-DXd, DS-8201a), an optimised antibody drug conjugate (ADC) is in clinical trials, showing promising outcomes in patients with advanced, nonoperable or metastatic HER2-positive breast cancer who had already undergone intensive prior treatment. Based on this data, T-DXd has already been approved in the US and Japan for HER2-positive advanced nonoperable and metastatic breast cancer – in the US after at least two prior anti-HER2 targeted treatment lines and in Japan after prior chemotherapy. T-DXd represents successful “antibody engineering”. Since the beginning of the year, T-DXd has also been approved in Europe as monotherapy for inoperable or metastatic HER2-positive breast cancer in patients who are pretreated with at least two anti-HER2 directed therapies. This paper presents strategies for improving treatment options in advanced nonoperable and metastatic HER2-positive breast cancer, with the development of T-DXd as an example.

show abstract

Section: Spotlight On “Antibody Engineering”mentioning

confidence: 99%

Section: Antikörper-wirkstoff-konjugat (Adc)unclassified

Section: Introductionmentioning

confidence: 99%

Section: Introductionunclassified

See 2 more Smart Citations

New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer

Lüftner

Peipp

2021

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

show abstract

“…Auf die Zulassungssituation hat die Marktrücknahme keinen Einfluss. Auch die Empfehlung der AGO-Kommission Mamma bleibt unverändert bestehen [2]. Die Kommission hat einen Musterantrag für die Kostenübernahme erstellt (www.ago-online.de).…”

Section: Transfer In Die Praxis Von Dr Carlota Claussen Und Pd Dr Maggie Banys-paluchowski (Lübeck)unclassified

Buparlisib in Kombination mit Tamoxifen: Rationale für zielgerichtete Therapie bei PIK3CA-mutiertem metastasierten Mammakarzinom bestätigt

Claussen¹,

Banys‐Paluchowski²

2021

Kompass Onkol

View full text Add to dashboard Cite

The PIKTAM study evaluated the efficacy and safety of the PI3K inhibitor buparlisib in combination with tamoxifen in hormone receptor-positive (HR+), HER2-negative advanced breast cancer patients after failure of prior endocrine therapy. In this open-label, single-arm phase II trial, 25 patients were enrolled in 11 sites in Germany. Patients were stratified according to PIK3CA mutation status (tissue and cfDNA from serum samples) and/or loss of PTEN expression. Patients received buparlisib (100mg) and tamoxifen (20mg) once daily on a continuous schedule (28-day cycle) until progression or unacceptable toxicity. Primary endpoint was overall 6-month progression-free survival (PFS) rate. Key secondary endpoints included the 6-month PFS rate in subpopulations, PFS, overall survival, overall response rate (ORR), disease control rate (DCR), and safety. Overall, the 6-month PFS rate was 33.3% (n/N = 7/21, one-sided 95% CI 16.8–100) and median PFS was 6.1 (CI 2.6–10.6) months. The ORR and DCR were 12.5% and 44%. The PIK3CA-mutated subgroup consistently showed the highest 6-month PFS rate (62.5%, n/N = 5/8), median PFS (8.7 months), ORR (40%), and DCR (80%). No new safety signals emerged. Most common adverse events were gastrointestinal disorders (56%), psychiatric/mood disorders (48%), skin rash/hypersensitivity (44%), cardiovascular (40%), and hepatic (32%) events. The trial was prematurely terminated due to the substantially altered risk – benefit profile of buparlisib. Nevertheless, PIK3CA mutations emerged as a clinically feasible and useful biomarker for combined PI3K inhibition and endocrine therapy in patients with HR+ breast cancer. Further biomarker – stratified studies with isoform – specific PI3K inhibitors are warranted. EudraCT No: 2014–000599–24.

show abstract

Management of Advanced Breast Cancer in Young Women: What’s New in Systemic Treatment

Ribeiro

Konsoulova

Paluch‐Shimon

et al. 2020

Breast Cancer in Young Women

View full text Add to dashboard Cite

AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2016

Cited by 24 publications

References 19 publications

New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer

New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer

Buparlisib in Kombination mit Tamoxifen: Rationale für zielgerichtete Therapie bei PIK3CA-mutiertem metastasierten Mammakarzinom bestätigt

Management of Advanced Breast Cancer in Young Women: What’s New in Systemic Treatment

Contact Info

Product

Resources

About